الفهرس | Only 14 pages are availabe for public view |
Abstract Background: Diabetes has become a widespread epidemic, primarily because of the increasing prevalence and incidence of type 2 diabetes. Diabetic polyneuropathy (DPN) is the most common chronic complication of diabetes. Incretin hormones promote stimulation of insulin secretion, inhibition of glucagon secretion, and they are directly neurotrophic. It was found that DPPI treatment improved motor and to a lesser extent sensory nerve conduction velocity. Objective: This study tried to evaluate the effects of incretin enhancer (DPPI: sitagliptin) given orally for streptozotocin induced diabetic peripheral neuropathy (DPN) in type II diabetic male rats |